NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype. (December 2022)

• Record Type: Journal Article
• Authors: Ramia de Cap, Maximiliano; Wu, Leo P.; Pihan, German A.; Narayanan, Damodaran; Morgan, Elizabeth A.; Pinkus, Geraldine S.; Cin, Paola Dal; Hurwitz, Stephanie N.; Bagg, Adam; Patel, Sanjay S.; Tam, Wayne; Ouseph, Madhu M.; Gagan, Jeffrey; Madanat, Yazan F.; Siddon, Alexa; Raess, Philipp W.; Rogers, Heesun J.; Bueso-Ramos, Carlos E.; Kanagal-Shamanna, Rashmi; Kurzer, Jason H.; Arber, Daniel A.; Hasserjian, Robert P.; Weinberg, Olga K.
• Is Part Of: Leukemia research. Volume 123(2022)
• Publication Date: 2022-12
• Subjects: Leukemia -- AML -- NPM1 -- Myeloid Sarcoma -- Cancer -- Genetics -- Oncology -- Pathology; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2022.106965
• Languages: English
• ISSNs: 0145-2126

Abstract

Graphical Abstract: ga1 Highlights: Complex karyotype (CK) is associated with adverse outcome in myeloid neoplasms (MN) with NPM1 mutation. MN with CK and NPM1 mutation have similar outcomes to MN with CK and TP53 mutation. MN with NPM1 mutation and CK are not associated with prior cytotoxic therapy.